• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Monte Rosa Therapeutics Inc (NQ: GLUE )

    9.250 +0.410 (+4.64%)
    Streaming Delayed Price Updated: 3:53 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 563,238
    Open 8.850
    Bid (Size) 9.240 (8)
    Ask (Size) 9.260 (2)
    Prev. Close 8.840
    Today's Range 8.420 - 9.270
    52wk Range 2.911 - 12.40
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
    The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga

    Performance

    YTD
    +62.00%
    +62.00%
    1 Month
    +82.45%
    +82.45%
    3 Month
    +147.33%
    +147.33%
    6 Month
    +60.59%
    +60.59%
    1 Year
    +178.61%
    +178.61%

    More News

    Read More
    PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    “Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
    Via AB Newswire
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Why Is Monte Rosa Therapeutics Stock Surging On Monday?
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Announces Leadership Team Promotions
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.